Molecular alterations in esophageal cancer

Soji Ozawa, Yuukou Kitagawa, Masaki Kitajima

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The clinicopathological characteristics of esophageal cancer have gradually been clarified using molecular biologic methods developed over the past 20 years. For example, amplification of the c-erb B gene is a prognostic factor and predictive of lymph node involvement, while the amplification of the cyclin D1 gene is also a prognostic factor and predictive of distant organ metastasis. Alteration of the p16 gene is also a prognostic factor and predicts lymph node involvement. As telomerase activity is almost a unique phenomenon of cancer cells, highly sensitive detection of esophageal cancer cells in the peripheral blood can be performed. Recently, such new methods as comparative genomic hybridization analysis and cDNA microarray analysis have been used to determine meaningful genetic changes. For therapeutic purposes, although tailor-made therapy has been proposed for several years, the validity of these approaches should be confirmed in a well-designed clinical trial. As molecular targeted therapies, tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR) and monoclonal antibodies against EGFR are being studied in clinical trials in Western countries. A clinical trial of p53 gene therapy against esophageal cancer is also promising.

Original languageEnglish
Pages (from-to)457-462
Number of pages6
JournalNippon Geka Gakkai zasshi
Volume103
Issue number6
Publication statusPublished - 2002

Fingerprint

Esophageal Neoplasms
Clinical Trials
Epidermal Growth Factor Receptor
Lymph Nodes
bcl-1 Genes
Molecular Targeted Therapy
p16 Genes
Comparative Genomic Hybridization
Telomerase
p53 Genes
Microarray Analysis
Oligonucleotide Array Sequence Analysis
Genetic Therapy
Protein-Tyrosine Kinases
Monoclonal Antibodies
Neoplasm Metastasis
Therapeutics
Genes
Neoplasms

Cite this

Ozawa, S., Kitagawa, Y., & Kitajima, M. (2002). Molecular alterations in esophageal cancer. Nippon Geka Gakkai zasshi, 103(6), 457-462.

Molecular alterations in esophageal cancer. / Ozawa, Soji; Kitagawa, Yuukou; Kitajima, Masaki.

In: Nippon Geka Gakkai zasshi, Vol. 103, No. 6, 2002, p. 457-462.

Research output: Contribution to journalArticle

Ozawa, S, Kitagawa, Y & Kitajima, M 2002, 'Molecular alterations in esophageal cancer', Nippon Geka Gakkai zasshi, vol. 103, no. 6, pp. 457-462.
Ozawa, Soji ; Kitagawa, Yuukou ; Kitajima, Masaki. / Molecular alterations in esophageal cancer. In: Nippon Geka Gakkai zasshi. 2002 ; Vol. 103, No. 6. pp. 457-462.
@article{d393da308b044395ac3ec55d76816af5,
title = "Molecular alterations in esophageal cancer",
abstract = "The clinicopathological characteristics of esophageal cancer have gradually been clarified using molecular biologic methods developed over the past 20 years. For example, amplification of the c-erb B gene is a prognostic factor and predictive of lymph node involvement, while the amplification of the cyclin D1 gene is also a prognostic factor and predictive of distant organ metastasis. Alteration of the p16 gene is also a prognostic factor and predicts lymph node involvement. As telomerase activity is almost a unique phenomenon of cancer cells, highly sensitive detection of esophageal cancer cells in the peripheral blood can be performed. Recently, such new methods as comparative genomic hybridization analysis and cDNA microarray analysis have been used to determine meaningful genetic changes. For therapeutic purposes, although tailor-made therapy has been proposed for several years, the validity of these approaches should be confirmed in a well-designed clinical trial. As molecular targeted therapies, tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR) and monoclonal antibodies against EGFR are being studied in clinical trials in Western countries. A clinical trial of p53 gene therapy against esophageal cancer is also promising.",
author = "Soji Ozawa and Yuukou Kitagawa and Masaki Kitajima",
year = "2002",
language = "English",
volume = "103",
pages = "457--462",
journal = "Nihon Geka Gakkai zasshi",
issn = "0301-4894",
publisher = "Nihon Geka Gakkai",
number = "6",

}

TY - JOUR

T1 - Molecular alterations in esophageal cancer

AU - Ozawa, Soji

AU - Kitagawa, Yuukou

AU - Kitajima, Masaki

PY - 2002

Y1 - 2002

N2 - The clinicopathological characteristics of esophageal cancer have gradually been clarified using molecular biologic methods developed over the past 20 years. For example, amplification of the c-erb B gene is a prognostic factor and predictive of lymph node involvement, while the amplification of the cyclin D1 gene is also a prognostic factor and predictive of distant organ metastasis. Alteration of the p16 gene is also a prognostic factor and predicts lymph node involvement. As telomerase activity is almost a unique phenomenon of cancer cells, highly sensitive detection of esophageal cancer cells in the peripheral blood can be performed. Recently, such new methods as comparative genomic hybridization analysis and cDNA microarray analysis have been used to determine meaningful genetic changes. For therapeutic purposes, although tailor-made therapy has been proposed for several years, the validity of these approaches should be confirmed in a well-designed clinical trial. As molecular targeted therapies, tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR) and monoclonal antibodies against EGFR are being studied in clinical trials in Western countries. A clinical trial of p53 gene therapy against esophageal cancer is also promising.

AB - The clinicopathological characteristics of esophageal cancer have gradually been clarified using molecular biologic methods developed over the past 20 years. For example, amplification of the c-erb B gene is a prognostic factor and predictive of lymph node involvement, while the amplification of the cyclin D1 gene is also a prognostic factor and predictive of distant organ metastasis. Alteration of the p16 gene is also a prognostic factor and predicts lymph node involvement. As telomerase activity is almost a unique phenomenon of cancer cells, highly sensitive detection of esophageal cancer cells in the peripheral blood can be performed. Recently, such new methods as comparative genomic hybridization analysis and cDNA microarray analysis have been used to determine meaningful genetic changes. For therapeutic purposes, although tailor-made therapy has been proposed for several years, the validity of these approaches should be confirmed in a well-designed clinical trial. As molecular targeted therapies, tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR) and monoclonal antibodies against EGFR are being studied in clinical trials in Western countries. A clinical trial of p53 gene therapy against esophageal cancer is also promising.

UR - http://www.scopus.com/inward/record.url?scp=0036594591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036594591&partnerID=8YFLogxK

M3 - Article

C2 - 12094695

AN - SCOPUS:0036594591

VL - 103

SP - 457

EP - 462

JO - Nihon Geka Gakkai zasshi

JF - Nihon Geka Gakkai zasshi

SN - 0301-4894

IS - 6

ER -